Scholarlink

Purpose <p>To report real-world clinical experience with [<sup>177</sup>Lu]Lu-PSMA-I&amp;T targeted radionuclide therapy (TRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) in a single tertiary referral university hospital.</p> Methods <p>Patients with mCRPC who were treated with [<sup>177</sup>Lu]Lu-PSMA-I&amp;T TRT as standard of care between February 2022 and August 2023 were included in this retrospective study. Patients were treated with a maximum of six cycles with a fixed activity of 7.4 GBq/100µg [<sup>177</sup>Lu]Lu-PSMA-I&amp;T per cycle.</p> Results <p>50 patients with mCRPC were included, of them 84% had prior therapy with two lines of taxane-based chemotherapy treated and at least one line of androgen receptor signaling inhibitor. A total of 126 cycles with a median of 2 cycles (IQR 1–6) [ <sup>177</sup>Lu]Lu-PSMA-I&amp;T were administered per patient. PSA declines of ≥ 50% and ≥ 70% were achieved in 16% and 10% of the patients, respectively. Radiological response was achieved in 11% of the patients. In total, 68 treatment-related Adverse Events (TRAEs) were observed, mainly grade 1–2 in 88% of cases. Grade 3/4 TRAEs were observed in 12% of cases. No grade 3 or higher xerostomia was reported. Median progression-free survival was 7.7 months (95% CI 4.0-11.3) and median overall survival was 8.1 months (95% CI 5.0-11.3).</p> Conclusion <p>In heavily pretreated patients with mCRPC, treatment of [<sup>177</sup>Lu]Lu-PSMA-I&amp;T TRT is well tolerated and safe, but real-world efficacy of [<sup>177</sup>Lu]Lu-PSMA appears lower compared to data from recent phase-3 clinical trials using a different radioligand [<sup>177</sup>Lu]Lu-PSMA-617. Further studies may show whether patients with mCRPC benefit more from [<sup>177</sup>Lu]Lu-PSMA when initiated at an earlier stage of treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月18日

查看全文
  • Sui wai Ling,
  • Quido de Lussanet de la Sablonière,
  • Michael Ananta,
  • Erik de Blois,
  • Stijn L. W. Koolen,
  • Roosmarijn C. Drexhage,
  • Johannes Hofland,
  • Debbie G. J. Robbrecht,
  • Astrid A M van der Veldt,
  • Frederik A Verburg,
  • Tessa Brabander

摘要

Purpose

To report real-world clinical experience with [177Lu]Lu-PSMA-I&T targeted radionuclide therapy (TRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) in a single tertiary referral university hospital.

Methods

Patients with mCRPC who were treated with [177Lu]Lu-PSMA-I&T TRT as standard of care between February 2022 and August 2023 were included in this retrospective study. Patients were treated with a maximum of six cycles with a fixed activity of 7.4 GBq/100µg [177Lu]Lu-PSMA-I&T per cycle.

Results

50 patients with mCRPC were included, of them 84% had prior therapy with two lines of taxane-based chemotherapy treated and at least one line of androgen receptor signaling inhibitor. A total of 126 cycles with a median of 2 cycles (IQR 1–6) [ 177Lu]Lu-PSMA-I&T were administered per patient. PSA declines of ≥ 50% and ≥ 70% were achieved in 16% and 10% of the patients, respectively. Radiological response was achieved in 11% of the patients. In total, 68 treatment-related Adverse Events (TRAEs) were observed, mainly grade 1–2 in 88% of cases. Grade 3/4 TRAEs were observed in 12% of cases. No grade 3 or higher xerostomia was reported. Median progression-free survival was 7.7 months (95% CI 4.0-11.3) and median overall survival was 8.1 months (95% CI 5.0-11.3).

Conclusion

In heavily pretreated patients with mCRPC, treatment of [177Lu]Lu-PSMA-I&T TRT is well tolerated and safe, but real-world efficacy of [177Lu]Lu-PSMA appears lower compared to data from recent phase-3 clinical trials using a different radioligand [177Lu]Lu-PSMA-617. Further studies may show whether patients with mCRPC benefit more from [177Lu]Lu-PSMA when initiated at an earlier stage of treatment.